NCT03952507

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

A Phase 1 Open-label Study in Healthy Subjects to Assess the Relative Oral Bioavailability and Food Effect of Single-dose JNJ-64417184 Administered as Tablets and as Suspension

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the relative bioavailability of JNJ-64417184, formulated as a test formulation (tablet) compared to a reference formulation (suspension), administered orally in a fasted state, in healthy participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-64417184 600 (Oral Tablet Formulation)	Participants will receive 600 mg of JNJ-64417184 as oral tablet.
DRUG	JNJ-64417184 (Oral Suspension Formulation)	Participants will also receive JNJ-64417184 600 mg as oral suspension.

Timeline

• Start date: 2019-05-15
• Primary completion: 2019-06-22
• Completion: 2019-06-22
• First posted: 2019-05-16
• Last updated: 2025-02-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study